A Form 4 filed on September 9, 2026 disclosed that Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), sold 23,429 shares of common stock on September 8, 2026 under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, Inc.
- Shares sold: 23,429 shares of common stock disposed of (transaction code S) on September 8, 2026.
- Weighted average price: $10.9158 per share, with individual sale prices ranging between $10.72 and $11.13.
- Remaining holdings: 1,449,765 shares of common stock held directly following the transaction.
- 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 13, 2026.
Details of Fred Aslan's Share Sale at Artiva Biotherapeutics
According to the Form 4 filing, Fred Aslan, who serves as both Chief Executive Officer and Director of Artiva Biotherapeutics, Inc., disposed of 23,429 shares of the company's common stock on September 8, 2026. The transaction was coded "S," indicating an open-market sale. The filing was signed by Jennifer Bush as Attorney-in-Fact and submitted to the SEC on September 9, 2026.
The filing disclosed a weighted average sale price of $10.9158 per share. According to footnote 2, the range of prices for the transaction was between $10.72 and $11.13. The filing further noted that full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder of the issuer. Following the reported transaction, Aslan directly holds 1,449,765 shares of common stock.
The filing indicated, via a checked box, that the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Footnote 1 specified that the applicable Rule 10b5-1 plan was adopted by the reporting person on May 13, 2026. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
The filing reported the sale of 23,429 shares of Artiva Biotherapeutics common stock by CEO Fred Aslan on September 8, 2026, at a weighted average price of $10.9158, conducted under a Rule 10b5-1 plan adopted May 13, 2026, leaving him with 1,449,765 shares held directly.






Please wait processing your request...